Get the latest Science News and Discoveries

Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC

None

Related news:

Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer - EurekAlert!